Payment overview · 2025
General Payments
$12,470.00
23 reported records · 5 companies
Healthcare provider profile · identity verified
Bradley P Fox, MD
Allopathic & Osteopathic Physicians|Family Medicine · ERIE, PA · NPI 1336124247
Verified facts
What the public records show
CMS Open Payments records show Bradley P Fox, MD received $12,470.00 in general payments during 2025 across 23 reported records.
Astellas Pharma US Inc accounted for 95.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $11,952.40 | 95.8% | 18 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $153.55 | 1.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $124.90 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $123.86 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.29 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,085.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,752.50 | 3 |
| Travel and Lodging | $2,634.96 | 6 |
| Food and Beverage | $997.54 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $11,952.40 | 18 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $153.55 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $124.90 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $124.90 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $115.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 715 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 125 |
| Lisinopril | Lisinopril | 392 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 104 |
| Simvastatin | Simvastatin | 251 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 212 | 66 |
| Ezetimibe | Ezetimibe | 189 | 60 |
| Omeprazole | Omeprazole | 189 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 56 |
| Metformin Hcl Er | Metformin Hcl | 162 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 56 |
| Gabapentin | Gabapentin | 155 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 34 |
| Clonazepam | Clonazepam | 118 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 40 |
| Famotidine | Famotidine | 103 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 31 |
| Furosemide | Furosemide | 102 | 34 |
| Sertraline Hcl | Sertraline Hcl | 102 | 27 |
| Montelukast Sodium | Montelukast Sodium | 96 | 28 |
| Losartan Potassium | Losartan Potassium | 92 | 33 |
| Metformin Hcl | Metformin Hcl | 87 | 29 |
| Valsartan | Valsartan | 83 | 29 |
| Atenolol | Atenolol | 82 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 17 |
| Xarelto | Rivaroxaban | 79 | 19 |
| Lorazepam | Lorazepam | 78 | 26 |
| Meloxicam | Meloxicam | 77 | 31 |
| Benazepril Hcl | Benazepril Hcl | 74 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | 20 |
| Tramadol Hcl | Tramadol Hcl | 67 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 22 |
| Irbesartan | Irbesartan | 64 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 63 | 19 |
| Trazodone Hcl | Trazodone Hcl | 63 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 23 |
| Indapamide | Indapamide | 62 | 18 |
| Potassium Chloride | Potassium Chloride | 61 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 15 |
| Carvedilol | Carvedilol | 57 | 18 |
| Allopurinol | Allopurinol | 53 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 16 |
| Jardiance | Empagliflozin | 49 | 15 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 12 |
| Eliquis | Apixaban | 46 | 17 |
| Alendronate Sodium | Alendronate Sodium | 45 | 17 |
| Estradiol | Estradiol | 45 | 15 |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Mirtazapine | Mirtazapine | 43 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 17 |
| Alprazolam | Alprazolam | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | 14 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Prednisone | Prednisone | 37 | 32 |
| Celecoxib | Celecoxib | 36 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 12 |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | 15 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | 12 |
| Prolia | Denosumab | 30 | 16 |
| Valacyclovir | Valacyclovir Hcl | 30 | 17 |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | 12 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Oxaprozin | Oxaprozin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 13 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 13 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Diazepam | Diazepam | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $12,470.00 · 23 records | Astellas Pharma US Inc | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Symbravo, VOQUEZNA, Veozah | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error